This afternoon we watched Humana drop -13.5% to a price of $443.49 per share. The large-cap Medical Specialities company is now trading -26.99% below its average target price of $607.48. Analysts have set target prices ranging from $568.0 to $640.0 per share for Humana, and have given the stock an average rating of buy.
The stock has a very low short interest at 1.3%, and a short ratio of 2.1. The company's insiders own 0.17% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 96.3% of Humana's shares being owned by this investor type.
Institutions Invested in Humana
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-03-31 | Blackrock Inc. | 9% | 11,281,944 | $5,003,467,795 |
| 2023-03-31 | Vanguard Group, Inc. (The) | 9% | 11,262,012 | $4,994,628,085 |
| 2023-03-31 | Price (T.Rowe) Associates Inc | 6% | 7,667,648 | $3,400,551,344 |
| 2023-03-31 | FMR, LLC | 6% | 7,342,938 | $3,256,544,599 |
| 2023-03-31 | Wellington Management Group, LLP | 6% | 7,348,011 | $3,258,794,441 |
| 2023-03-31 | State Street Corporation | 5% | 5,708,167 | $2,531,534,437 |
| 2023-03-31 | Capital International Investors | 4% | 4,370,090 | $1,938,106,108 |
| 2023-03-31 | GQG Partners LLC | 2% | 2,243,042 | $994,774,341 |
| 2023-03-31 | Geode Capital Management, LLC | 2% | 2,234,477 | $990,975,820 |
| 2023-03-31 | Capital Research Global Investors | 2% | 2,202,508 | $976,797,779 |
Besides an analyst consensus of strong upside potential, other market factors point to there being positive market sentiment on Humana.
